STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNWV
  4. [8-K] SANUWAVE Health, Inc. Reports Material Event

Sanuwave Health (Nasdaq: SNWV) receives $5M as intravascular patent option is exercised

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Sanuwave Health, Inc. reports that a third-party licensee has exercised its option to acquire a portfolio of Sanuwave, Inc. patents related to intravascular shockwave applications. The option exercise follows an exclusive license and option agreement originally entered into on March 6, 2024, which included a one-time $2.5 million payment for the exclusive license and option rights. Upon exercising the option on August 21, 2025, the licensee made an additional $5.0 million cash payment to Sanuwave, Inc., providing a further influx of cash tied to this patent portfolio.

Positive

  • None.

Negative

  • None.

Insights

Option exercise brings Sanuwave an additional $5.0M cash for its intravascular shockwave patent portfolio.

The company indicates that a third-party licensee has exercised an option to acquire a portfolio of patents covering intravascular shockwave applications. This option stems from an agreement dated March 6, 2024, under which Sanuwave, Inc. had previously granted the licensee an exclusive license and the related purchase option in exchange for a one-time $2.5 million payment.

With the option exercise on August 21, 2025, the licensee has now made an additional $5.0 million cash payment to Sanuwave, Inc. This represents a confirmed monetization event tied to that specific patent portfolio, turning earlier licensing and option rights into a completed cash transaction. The filing focuses on this cash receipt and does not elaborate on ongoing obligations or future revenue linked to these patents.

From an investor perspective, this disclosure highlights a concrete cash inflow associated with intellectual property in intravascular shockwave applications. Subsequent periodic reports may provide more detail on how this transaction influences the company’s financial position, strategy for remaining patents, or future licensing activities.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Understanding 8-K Material Events →
FALSE000141766300014176632025-08-212025-08-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)August 21, 2025
SANUWAVE Health, Inc.
(Exact name of registrant as specified in its charter)
Nevada001-4255220-1176000
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
9600 W. 76th Street, Suite 118,Eden Prairie,Minnesota55344
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code(952)656-1029
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)
Name of each exchange on which
registered
Common stock, par value $0.001 per shareSNWVThe Nasdaq Stock Market LLC

Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1

Item 8.01              Other Events.

As previously disclosed, on March 6, 2024, Sanuwave, Inc. entered into an exclusive license and option agreement with a third-party licensee (the “Licensee”) in connection with a portfolio of Sanuwave, Inc. patents related to the field of intravascular shockwave applications (the “Patents”). In exchange for a one-time payment of $2.5 million, Sanuwave, Inc. granted the Licensee an exclusive license to the Patents and an option to acquire the Patents, which option the Licensee exercised on August 21, 2025. In connection with such exercise, the Licensee made a $5.0 million cash payment to Sanuwave, Inc.

2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SANUWAVE HEALTH, INC.
Dated: August 21, 2025By:/s/ Morgan C. Frank
Name:Morgan C. Frank
Title:Chief Executive Officer
3

Source: View Original Filing on SEC EDGAR

FAQ

What did SANUWAVE Health (SNWV) announce in this 8-K?

The company reported that a third-party licensee has exercised its option to acquire a portfolio of Sanuwave, Inc. patents related to intravascular shockwave applications, triggering a new cash payment to Sanuwave, Inc.

How much cash does SANUWAVE receive from the option exercise?

Upon the option exercise on August 21, 2025, the licensee made a $5.0 million cash payment to Sanuwave, Inc. in connection with acquiring the intravascular shockwave patent portfolio.

What were the original terms of SANUWAVE’s patent license and option agreement?

On March 6, 2024, Sanuwave, Inc. entered into an exclusive license and option agreement granting a third-party licensee an exclusive license to a portfolio of intravascular shockwave patents and an option to acquire those patents, in exchange for a one-time $2.5 million payment.

Which SANUWAVE patents are involved in this transaction?

The transaction involves a portfolio of Sanuwave, Inc. patents related to the field of intravascular shockwave applications, which were first licensed and then acquired by the licensee upon exercising the option.